Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...

FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted ...

A Marathon Not a Sprint: Improving Outcomes for Patients With Metastatic Melanoma in 2022 and Beyond This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...

NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...

BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...

Dec 15 (Reuters) - Biocartis Group Nv : * Biocartis Group: CE-marking Idylla NRAS-BRAF mutation test completes offering of metastatic colorectal cancer tests for clinical use on Idylla platform Source ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...

Biomarker testing completion rates in patients with metastatic colorectal cancer (CRC) has increased over time in alignment with guidelines and US Food and Drug Administration (FDA) approvals, but ...